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Abstract
Background: Stem cell therapy with bone marrow-derived mesenchymal stem cells is a promising
tissue engineering strategy to promote regeneration of craniofacial bone.
Purpose: To determine whether cell therapy with ex vivo expanded stem cell populations would
be safe and efficacious in the regeneration of large alveolar defects in patients with a history of
cleft palate or craniofacial trauma.
Materials and Methods: Eighteen patients (10 patients with traumatic injury and 8 patients with
cleft palate) presenting with missing teeth associated with horizontal alveolar bone deficiencies
were included in this randomized controlled clinical trial. Patients were randomized to receive
either conventional autogenous block grafts or stem cell therapy. After a healing period of 4
months the treated sites were re-entered and the bone width re-assessed prior to implant place-
ment. Implant stability was evaluated through torque testing of the implant upon insertion and at
6 months postloading.
Results: The mean gain in bone width was 1.561.5 mm in the stem cell therapy group and 3.36
1.4 mm in the control group. Overall, bone gain was higher in trauma patients as compared to
patients with cleft palate, for both the control and the stem cell therapy groups. Most postopera-
tive complications were wound dehiscences and incision line openings. Implants were placed
successfully in 5 out of 10 patients in the stem cell therapy group and in all 8 patients in the con-
trol group. One implant from the control/cleft palate group failed before loading, while the rest of
the implants were loaded successfully and remained stable at 6 months. The patients who did not
receive implants were re-treated with autogenous block bone graft.
Conclusion: The ability of stem cells to treat large alveolar defects is safe, yet, their ability to com-
pletely reconstitute large alveolar defects is limited. This approach requires further optimization to
meet the outcomes seen using current methods to treat large defects, particularly those resultant
of cleft palate.
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1 | INTRODUCTION
Oral and craniofacial bone defects secondary to congenital diseases
(e.g. orofacial clefts) and trauma are very common and represent a sig-
nificant health care burden.1 Clefts of the lip and palate represent the
most common congenital malformations of the head and neck, with
approximately 7000 infants born with orofacial clefts in the US annu-
ally. The prevalence of cleft lip with or without cleft palate is 10.89 per
10 000 live births, and that of cleft palate is 6.45 per 10 000 live
births.2 Patients with clefts of the maxillary alveolus are frequently
missing teeth, typically the lateral incisors, either unilaterally or bilater-
ally.3 Regarding trauma, the vast majority of facial traumatic injuries are
attributed to motor vehicle accidents, falls, assaults, recreational and
sports injuries.4 Edentulous areas with large alveolar defects are also
observed in trauma related injuries of the orofacial complex. 4.1% of all
emergency room visits are attributed to primary traumatic injuries to
the head and neck region; injuries to teeth and dental structures are
quite common in these patients.5
In such cases of severe alveolar deficiencies, implant-prosthetic treat-
ment involving advanced bone grafting techniques is generally indicated
to restore optimum function and improve compromised esthetics. Cur-
rently, autogenous block bone grafts from intraoral (ramus, mandibular
symphysis) or extraoral sites (iliac crest, tibia) represent the standard-of-
care for alveolar grafting in cleft palate and trauma patients.6 However,
harvesting bone from an additional donor site has several potential disad-
vantages including longer surgical time, prolonged recovery, and morbid-
ity at the donor site including pain and neurosensory disturbances.
In an effort to overcome the limitations of current bone augmenta-
tion procedures, cell therapy by means of cell transplantation has
emerged as a possible strategy to regenerate alveolar bone. Recently,
there have been several clinical reports evaluating the use of stem cells
as a promising alternative approach for the reconstruction of alveolar
bone defects.7–11 We have previously demonstrated that the use of
autologous mixed cell populations containing stem cells enhance and
accelerate healing and regeneration of bone.9 Due to success in regen-
erating localized bone defects, the aim of this study was to evaluate
this approach for larger, more challenging alveolar defects.
This phase 1/2 feasibility trial had two objectives. The first was to
examine the safety and efficacy of an autologous cell therapy using a
mixed population of expanded autologous progenitor and stem cells
(ixmyelocel-t, Aastrom Biosciences, Inc.) to regenerate alveolar bone in
patients with alveolar defects resultant of cleft palate or trauma. The
second objective was to determine whether ixmyelocel-t therapy could
regenerate bone sufficient to enable the stable installation of dental
implants.
2 | METHODS
2.1 | Study design, patient selection, and
randomization
After US Food and Drug Administration and University of Michigan
Institutional Review Board (IRB) approval, 20 (twenty) subjects who
had horizontal alveolar ridge atrophy secondary to clefts (n510) or
trauma (n510), were selected to participate in this phase 1/2 random-
ized, controlled clinical trial. This sample size was chosen for feasibility
rather than statistical precision. Patients were fully informed about the
surgical procedures and treatment alternatives and signed an informed
consent. Following the screening examination performed by an exam-
iner, if the subjects met all inclusion and exclusion criteria, they were
enrolled by the study coordinator (Supporting Information study proto-
col document). A computer-generated randomization schedule was
used to randomly assign eligible subjects from each of the two groups
(cleft or trauma) to receive one of two possible treatments, either tradi-
tional autogenous bone grafting or stem cell therapy (ixmyelocel-t) (Fig-
ure 1A). Due to the nature of the stem cell therapy group requiring
bone marrow aspiration, patient and surgeon blinding was not possible.
Preoperative analyses included a complete medical history, blood draw
for lab studies (liver/renal panel, CBC), a clinical and radiographic exam-
ination of the stomatognathic system and a thorough evaluation of the
implant-recipient site with a cone-beam computed tomography (CBCT)
scan. The study timeline is outlined in Figure 1B. The primary outcome
of the study was the change in ridge width at re-entry which was
assessed clinically with open bone measures and radiographically with
CBCT. The measures were calculated between the baseline bone width
and the bone width of the healed ridge. Secondary outcomes included:
(1) the number of patients who required re-grafting, (2) the short-term
implant survival, and (3) patient centered outcomes-life quality
assessment.
2.2 | Ixmyelocel-t production
In the study participants who were designated to be in the stem cell
therapy group, 12–14 days before initial surgical treatment, 30–50 ml of
bone marrow was aspirated from the posterior iliac crest under con-
scious sedation and local anesthesia. Cell processing for generation of
the autologous cell product, ixmyelocel-t (Aastrom Biosciences Inc., Ann
Arbor, MI, USA), has been previously described.12 Briefly, the collected
marrow was transferred to a sterile blood bag and bone marrow mono-
nuclear cells (BMMNC) were purified by Ficoll density gradient centrifu-
gation. BMMNC were then inoculated into a bioreactor, which is a
proprietary computer-controlled, automated cell-processing unit, the
Aastrom Replicell System (Aastrom Biosciences). This system incorpo-
rates single-pass perfusion in which fresh medium flows slowly over the
cells without retention of waste metabolites or differentiating cytokines.
The culture medium consists of Iscove’s modified Dulbecco’s medium
(IMDM), 10% fetal bovine serum, 10% horse serum, and 5 mM hydro-
cortisone. After cultivation for 12 days at 378C, 5% CO2, with a ramped
continuous medium perfusion schedule, the Ixmyelocel-t product was
harvested by trypsinization, washed in a physiologic buffer, and col-
lected into a sterile bag, where it was stored until the time of transplan-
tation. The final cell composition was consisted of a mixture of bone
marrow-derived cells, including different concentrations of expanded
CD901 mesenchymal stem cells, CD141 monocytes/macrophages, and
mononuclear cells from the original bone marrow aspirate. The final cell
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product was suspended in Isolyte and 0.5% human serum albumin, and
transported in a sterile bag to the surgical suite.
2.3 | Bone regenerative procedure
Twelve to fourteen days after the bone marrow aspiration, alveolar
grafting was performed with the cell therapy (ixmyelocel-t) or an autog-
enous bone block harvested from an intraoral site (Figures 2 and 3). In
all patients, the surgery was performed under conscious sedation as
well as local anesthesia. Two surgeons performed all the surgeries. All
cleft surgeries were performed by the same surgeon while all trauma
surgeries were performed by the same surgeon. Full thickness muco-
periosteal flaps were raised on the facial and palatal/lingual aspects of
the bone defects. The alveolar crest width was measured with a vernier
caliper to the nearest half of a millimeter, 3 mm below the crest (base-
line width). Using a small round bur, the facial cortex was decorticated
to open up the bone marrow spaces in the defect site to facilitate graft
integration.
In the control sites, a cortico-cancellous block bone graft was har-
vested from the mandibular ramus or symphysis region. The size of the
graft was based on the size of the alveolar bone defect. Once the graft
was sized appropriately for ideal bone contact, fixation was achieved
with positional bone screws. Voids around the block graft were filled
with allogeneic particulate bone graft (either freeze dried bone allograft
or Puros cortical allograft, Zimmer). The particulate graft was stabilized
in the site with a collagen barrier membrane (CollaTape, Zimmer). For
the stem cell therapy group, a unit dose* of Ixmyelocel-T (10 ml) was
mixed with a commercially available b-TCP (beta tricalcium phosphate;
FIGURE 1 Trial profile. (A) Consort diagram of patient distribution and (B) study timeline
*A unit dose of IXMYELOCEL-T is the cells produced from a single run
patient batch derived from an inoculum of 255 3 106 cells into a standard
AastromReplicell Cell Cassette processed in the current version of the
AastromReplicell System.
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Cerasorb), which was used as a carrier to deliver the cells. The number
of cells mixed per unit volume of b-TCP was within the optimum range
as determined in preclinical studies (15 3 106–44 3 106 Ixmyelocel-T/
ml). The amount of b-TCP used ranged from 2.0 to 5.0 cc for each
patient. The total amount of b-TCP used depended on the number of
Ixmyelocel-T grafted, with the final dosage being 15–44 3 106 Ixmye-
locel-T/cc b-TCP. A resorbable cross-linked collagen membrane (Con-
Form; ACE surgical) was placed for graft containment and secured with
membrane tacks or screws. The labial flap was mobilized via periosteal
scoring incisions and supraperiosteal dissection. The flaps were then
repositioned and approximated with bioabsorbable sutures in a
tension-free manner. Primary closure was obtained in all cases.
2.4 | Postoperative care
Oral hygiene instructions included 0.12% Chlorhexidine mouth rinses
and no brushing in the surgical area for 2 weeks, to reduce the risk of
oral infection. Patients were prescribed oral antibiotics (Amoxicillin
500 mg every 8 hours for 7 days), and ibuprofen 600 mg (every 6
hours for 3 days). Follow-up examinations were performed at two
weeks and at 4 weeks following surgery. Patients were next seen for
re-entry and implant placement at 4 months.
2.5 | Re-entry
Re-entry procedures of the grafted sites were performed at 4 months
postgrafting. Prior to re-entry, another CBCT was recorded for surgical
planning of the implant placement to evaluate the extent of augmenta-
tion. Following mucoperiosteal flap elevation and debridement, the
healed crest width was measured again with a caliper (re-entry width).
Dental implants (Straumann, Nobel Biocare, Implant Direct, Zimmer) of
appropriate size were placed in the regenerated sites only in cases
where sufficient bone was present and primary implant stability could
be achieved. If primary stabilization of an implant could not be
achieved, additional grafting was performed using the same standard
of care procedure as in the control group and the area was allowed to
heal for an additional 4 month period, before being re-entered for
implant installation. In cases where primary stability was achieved but
FIGURE 3 Stem cell therapy case (A) Defect of the anterior alveolar ridge (B) Titanium screws in place. (C and D) Ixmyelocel-t mixed with
b-TCP and covered with collagen membrane. (E) Clinical situation at 4 month re-entry. (F and G) Dental implants placed into grafted bone.
(H) Final prosthesis delivery
FIGURE 2 Control case. (A) Horizontal alveolar ridge deficiency in the anterior maxilla. (B) A block graft harvested from the symphysis was
fixed with titanium screws. (C) The block graft was covered with particulate allograft. (D) The augmented site was further protected with a
collagen membrane. (E) Upon re-entry at 4 months the occlusal view clearly demonstrates the horizontal gain of bone width. (F and G) Two
implants placed in a correct oro-facial position. (H) Final prosthesis delivery
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residual bone deficiencies remained at the time of implant placement
causing implant thread exposure, additional bone grafting was per-
formed with freeze dried bone allograft (FDBA) in combination with a
collagen membrane (conForm, ACE).
2.6 | Short-term implant survival
The ability of the dental implant fixtures to remain stable was eval-
uated at 6 months postloading. Implants were considered failures if
they did not osseointegrate in the regenerated bone prior to loading
with the final prosthesis or if they developed fibrous encapsulation fol-
lowing loading. Osseointegration was evaluated based on clinical
implant stability (primary stability upon implant placement, as well as
torque testing) and radiographic examination.
2.7 | Statistical analyses
Descriptive statistics were used to summarize and describe the data.
No statistical test was implemented to evaluate differences in bone
gain between the groups due to the small sample size. Additionally, no
direct comparison of adverse events among the groups was performed.
Values are presented as means6SD.
3 | RESULTS
A total of 18 patients were enrolled and 17 completed the study.
Based on the compromised clinical outcomes observed in patients who
received the cell therapy in the cleft group, enrollment was held to 8
patients for this cohort. The baseline demographic characteristics of all
study participants are displayed in Table 1. In each patient, from one to
three sites were treated; as such, a total of 28 sites were grafted
(Table 2). Table 3 illustrates the previous surgical procedures that were
performed in the cleft palate patients. Note that in the cleft cohort,
only 8 of the originally planned 10 patients were enrolled because the
compromised clinical outcomes seen in the treatment group (cell ther-
apy) relative to the control group in this cohort contraindicated addi-
tional participant accrual.
No serious, study related adverse events were reported in examina-
tion of comprehensive safety assessments during the trial (Table 4). Most
postoperative complications were wound dehiscences and this occurred
in 2 patients (one from control/cleft group, and one from cell therapy/
cleft group), with symptoms of infection present in the cell therapy/cleft
patient. In three patients from the stem cell therapy trauma group the
surgical sited had to be resutured because of incision line opening. In one
patient who received a symphysis graft, mild pain and dysthesia of the
donor site were reported after the procedure and the symptoms resolved
within one week. Other postoperative complications included mild
edema and erythema in the surgical site, tooth sensitivity and prosthesis
related complications. The complete description of each reported
adverse events is presented in Supporting Information Table S1.
Pre-operative ridge dimensions and changes for the different
groups are presented in Table 5. The mean width of the initial alveolar
ridge was 3.661.6 mm for the control group and 2.961.3 mm for
the stem cell therapy group. At re-entry, the healed augmented
alveolar crest had a mean width of 6.961.3 mm for the control group
and 4.561.8 mm for the stem cell therapy group. The mean
calculated gain of horizontal ridge augmentation was 3.361.4 mm and
1.561.5 mm for the control and cell therapy group respectively. One
patient with cleft palate who received the stem cell therapy presented
with 1.5 mm loss of alveolar bone width at re-entry. All the other
patients with cleft palate who received the ixmyelocel-t gained from
0.5 to 2 mm of bone width. The respective gain in bone width for the
patients with trauma was from 0.5 to 5 mm. The mean bone gain was
higher in trauma patients as compared to cleft palate patients for both
the control and stem cell therapy group (Figure 4).
Augmented sites allowed for proper implant placement in all eight
patients of the control group and in 5 out of 10 patients of the stem
cell therapy group. Two of those five patients of the stem cell therapy
TABLE 2 Number and location of sites (n528) to be augmented
per patient (n517)
Number
of sites
n
patients
n
sites Location: n sites
One site 7 7 Maxilla, anterior (incisors, canines): 5
Mandible, anterior (incisors, canines): 2
Two sites 9 18 Maxilla, anterior (incisors, canines): 14
Mandible, anterior (incisors, canines): 2
Maxilla, posterior (premolars, molars): 2
Three sites 1 3 Maxilla, anterior (incisors, canines): 3
Total 17 28 Maxilla, anterior (incisors, canines): 22
Maxilla, posterior (premolars, molars): 2
Mandible, anterior (incisors, canines): 4
TABLE 3 History of previous surgeries in the area of graft in
patients with cleft palate
Control
Stem cell
therapy
Number of previous
surgeries related to cleft
palate (mean)
5 8
Number of previous
bone grafts (mean)
2 2
Source of previous
bone graft
Iliac crest, tibia,
alveolar bone
Iliac crest,
alveolar bone
TABLE 1 Patient characteristics/demographics
Control
Stem cell
therapy
Total number of patients 8 9
Number of patients
(Trauma/Cleft palate)
5/3 5/4
Mean age (Range) 31 (19–54) 27 (18–42)
Gender (Male/Female) 5/3 7/2
Ethnicity
Caucasian 6 7
Hispanic 1 1
African American 1 1
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group who received implants belonged to the cleft palate group and
the remaining three belonged to the trauma group. The patients who
did not receive implants were retreated with autogenous block bone
graft and were allowed to heal for an additional period of 4 months
(Table 6). Among the patients that received implants additional bone
augmentation procedures were performed in two control patients and
three Ixmyelocel-T patients. The additional bone augmentation proce-
dures included the use of either autogenous bone chips or freeze dried
bone allograft (FDBA) in combination with a collagen membrane (con-
Form, ACE or Zimmer).
One implant from the control/cleft palate group did not achieve
osseointegration and had to be removed. The rest of the implants were
loaded successfully and remained stable at three and 6 months post
loading. The abutments were well adapted to the implant fixture and
the restorations were functional.
In order to assess whether the cell transplantation treatment
affected the quality of life of the patients, all subjects were asked to
complete a questionnaire at the end of the study (Supporting Informa-
tion Table S2). Two patients from the control group reported that the
procedure resulted in significant discomfort and another two that the
procedure interfered with the daily activities. The results were similar
in the stem cell therapy group where two patients reported that the
procedure resulted in significant discomfort and another two that the
procedure interfered with the daily activities. Subjects from both
groups reported that they were satisfied with the outcome of the pro-
cedure, would recommend this procedure to other individuals, and
would do it again if necessary.
4 | DISCUSSION
Our clinical trial was designed to evaluate the safety and efficacy of an
autologous stem cell therapy for the regeneration of large, complex
alveolar bone defects. Though the prospect of stem cell therapies
offers significant advantages over traditional approaches for oral and
craniofacial reconstruction, there has been very limited translation of
this work toward clinical applications. One of the major limitations lies
in the inadequate characterization, as well as the variability in the
methods of isolation and ex vivo expansion of the cell populations.9 A
defining element of ixmyelocel-t therapy is the ability to employ repro-
ducible cell isolation and expansion protocols that can predictably yield
consistent cell populations, characterized by the presence of CD901
mesenchymal stem cells, CD141 monocytes/macrophages, and mono-
nuclear cells.8
Bone marrow osteoprogenitor cell delivery via local injection has
been used in orthopedics for a number of years for the treatment of
nonunion and critical-sized segmental defects.13 Besides the local injec-
tion of SSCs into the site of injury, other methods of cell transplantation
include the use of various carriers such as demineralized bone matrix or
hydroxyapatite scaffolds.14 Ex vivo expanded SSCs loaded onto resorb-
able scaffolds have been successfully used in the treatment of idio-
pathic osteonecrosis of the femoral head, “critical-sized” long bone
defects, spinal fusion and total hip arthroplasty.15–17 Outside of ortho-
pedics, there are limited reports of bone marrow derived mesenchymal
stem cells being used for the treatment of craniofacial bone defects aris-
ing from trauma and congential defects,7,10,18; yet, no randomized con-
trolled clinical trial involving implant therapy has been reported.
The results of the current clinical study showed that this cell ther-
apy is capable of osseous regeneration, confirming the results of our
previous randomized controlled clinical studies where ixmyelocel-t
therapy was evaluated in bone regeneration of extraction sockets and
bone reconstruction of maxillary sinuses.8,9,11 In the present study
however, the ability of these cells to completely reconstitute a large
craniofacial defect was limited, particularly in the patients with cleft
palate. It is well-established that in patients with large cleft lip and
TABLE 5 Clinical measurements of alveolar ridge width in mm
Ridge width in mm
(mean6 SD)
Control
Cleft
Control
Trauma
Control
ALL
Stem cell
therapy Cleft
Stem cell
therapy Trauma
Stem cell
therapy ALL
Baseline width 561.1 2.96 1.3 3.66 1.6 2.66 1.6 3.161.1 2.96 1.3
Re-entry width 6.761.6 76 1.2 6.96 1.3 3.26 1.7 5.361.5 4.56 1.8
Gain of crest width 1.761.2 4.16 0.7 3.36 1.4 0.66 1.3 2.161.4 1.56 1.5
TABLE 4 Frequency distribution of adverse events
Adverse event
Control
(Cleft)
Control
(Trauma)
Stem cell
therapy
(Cleft)
Stem cell
therapy
(Trauma)
Wound dehiscence 1 1
Infection 1
Incision line opening 3
Membrane exposure 1
Localized erythema 1 1
Localized edema 2 1
Tooth sensitivity 1
Pain and dysesthesia
in donor site
1
Early suture removal
(subject chewing
on surgical site)
1
Early implant failure 1
Implant supported
bridge came off
1 1 1
Abutment screw fracture 1
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palate deformities, sufficient mucosa of adequate vascularity is typically
missing owing to the nature of the defect itself or to scarring from prior
surgical procedures.19,20 Scar tissue may have a poor blood supply with
low oxygen tension, and when it is used to cover a bone graft, healing
can be compromised.21,22 These are important considerations in the
cleft palate cohort of this study. All of the patients with a history of
alveolar clefting had already undergone at least 5 prior surgical proce-
dures at the defect site, and in some instances more than eight hard or
soft tissue surgical procedures (Table 3). These sites exhibited palatal
and labial mucosal scaring, along with dense fibrous and hypovascular
submucosal tissue. These variables created significant surgical chal-
lenges and ultimately impacted the clinical outcomes of the bone graft-
ing procedures.
Success of the bone augmentation procedure is defined as the
ability to place implants with adequate primary stability. In our study,
horizontal bone augmentation was successful in 3 of 5 patients who
received cell therapy for the treatment alveolar defects secondary to
trauma. The cell therapy for treatment of alveolar cleft was successful
in 2 out of 5 subjects.
One of the other important factors for successful bone tissue regen-
eration is the ability to maintain space over the grafted bone, which
allows the formation of an undisturbed blood clot and healing.23 Several
techniques that have been used to maintain the space in noncontaining
large alveolar defects include the use of graft materials such as autoge-
nous block grafts or mineralized particulate bone grafts, as well as tita-
nium tenting screws.24–26 In the present study the carrier for stem cells
was ß-TCP in a granular form, of which 90% has been shown to resorb
in 3 months.27,28 This matrix carrier may be suitable for smaller more
localized defects but for larger defects, may not be suitable due to col-
lapse within the defect, leading to a suboptimal regenerative outcome in
the stem cell treatment group. Our goal was to compare the efficacy of
the cell transplantation therapy using particulate ß-TCP as a carrier to
the standard of care procedure for the regeneration of large alveolar
defects. Therefore, our control treatment did not include the carrier
alone (ß-TCP), but the use of autologous block bone graft which is con-
sidered the standard of care for large alveolar defects.6
Another limitation of predictable bone regeneration in these chal-
lenging defects might be due to the inability to “tailor” the delivery of
cells to the shape variability of patient-specific defects. Pre-clinical
studies using human bone marrow mononuclear cells or human bone
marrow derived mesenchymal stem cells have shown that the seeding
efficacy on b-TCP is generally high and cells stay attached to b-TCP
for 3 weeks although differences exist between various HA/TCP
ratios.29,30 To our knowledge no preclinical studies have assessed the
adhesion of the ixmyelocel-t cells on b-TCP. It is therefore possible
that the cells may have migrated out of the defect and therefore not
have contributed to regeneration. Alternatively, an ideal approach
would be one that is standardized enough to be reproducible, yet
adaptable enough to be patient- and defect-specific. Future studies
should consider stem cell transplantation on 3-dimensional (3-D)
printed scaffolds produced in the morphological dimensions of patient-
specific craniofacial defects.31,32
Postoperative evaluation time is another element that has a great
variation in different studies. Generally, healing time for large guided
bone regeneration procedures has been reported to be between 5 and
13 months.33–36 The rationale for our choosing the 4-month time point
for re-entry was based on the results of previous study on using auto-
logous cell therapy for reconstruction of localized craniofacial defect.8
In that study it was shown that autologous cell therapy accelerates
wound repair in extraction sockets, however, in larger defects, these
processes may require longer healing periods with this approach.
Besides evaluating the safety and efficacy of this new approach, we
also aimed to acquire information relative to the treatment protocol
from the patient perspective. This quality-of-life assessment is often
overlooked or not reported when trying to determine the initial feasibil-
ity of emerging therapies; yet, if the therapy is deemed effective, these
factors could underscore the acceptance and widespread use of these
procedures. Our study found that the acceptance of the cell therapy is
similar to the acceptance of the conventional treatment with autoge-
nous block graft. Most patients reported that the procedures involved
did not result in significant discomfort and did not significantly impact
their daily life activities. All participants from both groups reported that
they were satisfied with the final outcome and that if necessary, they
would undergo them again. This is in contrast with other studies
TABLE 6 Clinical outcomes
Outcome Control (Cleft)
Control
(Trauma)
Cell therapy
(Cleft)
Cell therapy
(Trauma)
Patients requiring re-grafting with block grafts 0 of 3 0 of 5 3 of 5 2 of 5
Patients reconstructed with implants 3 of 3 5 of 5 2 of 5 3 of 5
Patients requiring additional grafting at implant placement 0 of 3 2 of 5 2 of 2 1 of 3
FIGURE 4 Changes in alveolar ridge width in patients with a
history of cleft palate and traumatic injury
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reporting that most patients would not elect to undergo bone regenera-
tion procedures with autogenous grafts again if necessary because of
the associated postoperative pain and distress.37
5 | CONCLUSIONS
Our study demonstrated that transplantation of autologous stem cells
can be used safely for the reconstruction of large craniofacial defects.
Although the ability of ex vivo expanded autologous stem cells to com-
pletely reconstitute a large alveolar defect in adults is limited, these
cells are capable of osseous regeneration. This study provided insight
into factors that are critical for successful bone regeneration. Consider-
ations for future investigations would include longer postoperative
evaluation time periods, different scaffold material, and mode of deliv-
ery techniques which could potentially utilize customized scaffold/
matrix designs. Larger multicenter randomized controlled clinical trials
are necessary for the widespread use of this approach to enhance
bone regeneration in large alveolar and craniofacial defects.
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